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Abstract
Background: Although cervico-vaginal epithelial cells of the female lower genital tract provide the initial defense system
against HIV-1 infection, the protection is sometimes incomplete. Thus, enhancing anti-HIV-1 humoral immunity at the
mucosal cell surface by local expression of anti-HIV-1 broadly neutralizing antibodies (BnAb) that block HIV-1 entry would
provide an important new intervention that could slow the spread of HIV/AIDS.
Methods and Findings: This study tested the hypothesis that adeno-associated virus (AAV)-BnAb gene transfer to cervico-
vaginal epithelial cells will lead to protection against HIV-1. Accordingly, a recombinant AAV vector that encodes human
b12 anti-HIV gp120 BnAb as a single-chain variable fragment Fc fusion (scFvFc), or ‘‘minibody’’ was constructed. The
secreted b12 minibody was shown to be biologically functional in binding to virus envelope protein, neutralizing HIV-1 and
importantly, blocking transfer and infectivity of HIV-1bal in an organotypic human vaginal epithelial cell (VEC) model.
Furthermore, cervico-vaginal epithelial stem cells were found to be efficiently transduced by the optimal AAV serotype
mediated expression of GFP.
Conclusion: This study provides the foundation for a novel microbicide strategy to protect against sexual transmission of
HIV-1 by AAV transfer of broadly neutralizing antibody genes to cervico-vaginal epithelial stem cells that could replenish
b12 BnAb secreting cells through multiple menstrual cycles.
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Introduction
The mechanisms of HIV-1 transmission through the vaginal
route in women are still poorly understood. Epithelial cells lining
the mucosal surfaces of the female genital tract provide the first
line of defense against sexually transmitted pathogens such as
HIV-1 [1,2]. The multilayer squamous cell epithelia lining the
vagina and ectocervix provide a more substantial barrier against
HIV-1 invasion than the single layer columnar epithelium that
lines the endocervix [3]. Epithelial cells also produce several
biological factors, such as defensin, lactoferrin and secretory
leukocyte protease inhibitor (SLPI) that have anti-HIV properties
[1,3,4,5,6]. However, any damage or disruption to the epithelial
layer, which can occur as a result of inflammation from sexually
transmitted diseases (STDs) or even mild trauma during sexual
intercourse may increase the ability of HIV-1 to penetrate the
mucosal epithelial barrier. In addition, several cell surface
receptors and molecules have been reported to facilitate HIV-1
entry into epithelial cells allowing passage through the mucosal
barrier. Syndecans (expressed on the vaginal epithelial cells), for
example, were found to be exploited by HIV-1 to cross the
mucosal epithelium by transcytosis [7,8,9,10]. It has been reported
that the Arg298 in gp120 mediates HIV-1 binding to syndecans,
and the human b12 anti-HIV gp120 BnAb can block this
interaction [8,11,12,13].
The b12 molecule is one of a growing number of human BnAbs
including, 2G12, 2F5, 4E10, Z13e1, VRC01, HJ16, PG9 and
PG16 that are capable of potently neutralizing a broad range of
primary HIV-1 isolates [12,14]. B12 was originally isolated as an
antibody fragment (Fab), which recognizes a highly conserved
epitope on the viral gp120 envelope protein involved in binding to
CD4 on host cells [12]. In addition, b12 IgG1 can inhibit transfer
of cell-free HIV-1 to the ME-180 human cervical epithelial cell
line and block viral attachment to and uptake by epithelial cells
[15]. Macaques treated with b12 IgG1 by intravenous or
intravaginal (topical) application were shown to be protected
against simian human immunodeficiency virus (SHIV) infection by
the vaginal route [16]. These studies support the choice of b12
mAb to investigate the hypothesis that genetic transfer of a BnAb
to cervico-vaginal cells can confer protection from viral infection
at the mucosal surface.
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a variety of tissues and cell types [17,18,19,20,21,22] with the
potential of directing long-term expression from months to years
since the vector persists predominantly in episomal form
[17,19,21,23]. However, the upper layer of the cervico-vaginal
mucosa continuously sheds. In contrast, the basal layer of the
mucosa including the epithelial stem cells is maintained as a
replenishing source of squamous epithelial cells. Accordingly,
targeting the genital epithelial stem cells for transduction by AAV
would be ideal for stable and durable gene transfer in vivo.
Therefore, a major aim of this study was to investigate the
possibility of transducing female genital epithelial stem cells.
In the present study, an AAV vector was utilized for transfer of
the b12 antibody gene to cervico-vaginal epithelial cells. In
particular, a recombinant AAV-6 expressing b12 minibody was
produced and the minibodies secreted from transduced cells in an
organotypic vaginal epithelial cell (VEC) model demonstrated
their ability to inhibit transfer and infectivity of HIV-1 at levels
comparable to full-length b12 IgG1 MAb. Transduction of
primary genital-epithelial stem cells was also demonstrated. The
findings of this study demonstrate that use of the AAV vector to
express neutralizing human anti-gp120 minibodies is a promising




Human cervical and VEC lines and huPGECs used in this study
were cultured in keratinocyte serum-free medium provided with
supplementary bovine pituitary extract and recombinant human
Epidermal Growth Factor (EGF). The medium was further
supplemented with 100 units/ml penicillin, 100 mg/ml strepto-
mycin and CaC12 to a final calcium concentration of 0.4 mM.
DMEM/F12 medium was supplemented with 10% fetal bovine
serum (FBS). All media and supplements were obtained from
Invitrogen Corp. (Carlsbad, CA).
Cell lines and viruses
The human cell lines VK2/E6E7, Ectl/E6E7 and Endl/E6E7,
originally constructed in the laboratory of Deborah Anderson [24]
and obtained from the American Type Culture Collection
(ATCC, Manassas, VA), were cultured in calcium-supplemented
(0.4 mM) keratinocyte serum-free medium. TZM-bl cells were
acquired from the National Institutes of Health AIDS Research
and Reference Reagent Program (NIH-ARRRP, Germantown,
MD). TZM-b1 cells are a CXCR4-positive HeLa cell line that
expresses the cellular receptor (CD4) and co-receptor (CCR5) for
HIV-1. The cell line also contains integrated reporter genes for
luciferase and E. coli beta-galactosidase, under the control of an
HIV long-terminal repeat sequence (tat gene) which allows for
quantification of HIV infection. 293T cells and COS-1 (both from
ATCC) and TZM-bl cells were cultured in DMEM medium
supplemented with 10% FBS and 1% penicillin/streptomycin
(Invitrogen). All cells and cultures were maintained at 37uCi na
5% CO2 humidified incubator. The R-tropic HIV-1bal strain
(NIH-ARRRP) used for the transwell studies were only passaged
in human PBMCs and titered by the standard Reed and Muench
method [25].
Organotypic VEC culture and HIV-1 transmission model
Organotypic EpiVaginal
TM tissues (VEC-100: Nunc
TM single
well tissue culture plate inserts; pore size =0.4 mm; inner
diameter =0.80 cm) were purchased from MatTek Corp. (Ash-
land, MA) and maintained with proprietary growth medium
according to the company’s instructions. Fully differentiated
stratified squamous epithelial layers were maintained on the cell
culture insert membranes to allow growth at the air–liquid
interface. The integrity of the VEC tissues on the transwell filters
were verified using Trans Epithelial Electric Resistance (TEER)
readings (.300 ohm) and permeability to 70 kDa Dextran-
Rhodamine B (Sigma Corp., St. Louis, MO) applied to the apical
layer of the tissue and measuring paracellular passage of the dye
into the lower transwell chamber. We adapted the procedure by
Bobardt et al., 2007 to examine the effects of the b12 minibodies or
of AAV-6 expressing b12 minibody transduction on HIV-1
transfer through the multilayered VEC tissue. The b12 minibodies
or full-length b12 IgG1 (10 mg/ml) were pre-incubated with or
without HIV-1bal virus (50 ng of p24) in a total of 100 ml VEC
tissue growth media for 1 h before applying to the apical surface of
the EpiVaginal
TM tissues in the transwell inserts. The media from
the lower chamber were then collected at different time points to
determine infectivity of HIV-1bal virions that have crossed the
vaginal epithelial tissues by incubation of the samples with TZM-
bl cells as described below.
Production of AAV serotypes expressing GFP and b12
minibody
AAV serotypes 1, 2, 5, 6, 8, and 9 expressing GFP were
produced at Harvard Gene Therapy Initiative (Harvard Institute
of Medicine, Boston, MA), whereas AAV serotypes 3 and 4
expressing GFP were obtained from the AAV core at the
University of North Carolina, Chapel Hill. AAV-6 expressing
b12 minibody was obtained commercially (Virapur LLC, San
Diego, CA).
Construction of pTR-b12scFvFc expression vector
To construct the b12 minibody expression cassette, the b12scFv
sequence was PCR amplified from a DNA plasmid kindly
provided by Dennis Burton (The Scripps Research Institute, La
Jolla, CA) using primers to add flanking SfiI and NotI restriction
sites for insertion into the pTRUF hingestuffer vector (described
below) to yield pTR-scFvFc b12. The pTRUF hingestuffer vector
was created by our laboratory as follows. The IgG1 Fc sequence
(AF150959) was cloned into the pTRUF20 vector at NotI and ClaI
sites. The resulting pTRUF hingestuffer vector therefore could be
used to insert scFv sequences at the SfiI-NotI sites for expression
and secretion of scFvFc fusion proteins (directed by the leader
sequence of the human IgG VH4 gene family) when transfected in
mammalian cells alone or for production of recombinant AAV
expressing the scFvFc.
The pTR-b12scFvFc vector, constructed as described, readily
expressed b12 minibodies proteins which are secreted from
transfected 293T cells. Typical yields of secreted protein after 3
days of transfection ranged between 10–15 mg/ml (data not
shown). By SDS-PAGE gel analysis, the b12 minibody monomer
was shown to be approximately 55 kDa in reducing conditions
and at 110 kDa under non-reducing conditions, as expected (data
not shown).
Transduction of cells, flow cytometry analysis and
fluorescence microscopy
For AAV transduction, 5610
4 cells were incubated in 24 well
plates with AAV (1, 2, 3, 4, 5, 6, 8, 9)-GFP (10
10 genomic copies)
for 4 h with the VK2/E6E7, Ectl/E6E7 and Endl/E6E7 cells or
overnight for primary cells. Subsequently, the medium was
replaced, and the cells were examined on day 3. Expression of
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Becton Dickinson) and represented as percentage of GFP positive
cells, as well as visually assessed by fluorescence microscopy. To
evaluate transduction of the stem cell population in huPGECs with
AAV-6-GFP, the dissociated cells were immunostained for surface
Ck17 (Dako, CA) and nuclear p63 (Santa Cruz Biotechnology,
CA) cervical stem cell markers [26]. The GFP positive cells were
sorted using a FACSAria (Becton Dickinson) instrument after
gating on Ck17+p63+double positive cells, and images were
captured under a fluorescence microscope.
Immunohistochemical staining of paraffin-embedded
human vaginal, ectocervical and endocervical tissues
This study was approved by the Institutional Review Boards of
Boston University Medical School and Brigham and Women’s
Hospital Boston MA. All tissue samples were fixed in a solution of
95% ethanol and 5% acetic acid and processed for embedding in
wax. For immunohistochemical staining 5micron sections were
cut, mounted on glass slides then de-waxed and rehydrated
followed by a blocking step with a serum –free protein solution
(Dako, Carpinteria, CA,USA) for 30 min.This was drained from
the sections and then they were incubated with the rabbit primary
antibody p63 (Santa Cruz, CA, USA) at a dilution of 1:50 for
60 mins.Sections were then washed in Tris-buffered saline
containing 0.1% Tween 20 (TBST).The primary antibody was
detected by incubating the sections with a proprietary secondary
reagent (alkaline phosphatase Envision Dako) for 30 mins.followed
by 265 min. washes in TBST. Finally the antibody was visualized
by treating the sections with a substrate for alkaline phosphatase
(Fast Red Dako) that stains positive cells a bright red. After
washing the sections were counterstained with aqueous hematox-
ylin mounted in a glycerin-based medium and cover slipped.
Isolation of huPGECs
Human cervical tissue samples were obtained from patients who
had undergone hysterectomies. These tissues were procured with
informed consent by the National Disease Research Interchange
(NDRI, Philadelphia, PA). All tissues were placed in cold DMEM
medium with gentamicin (Invitrogen), and epithelial cells were
isolated within 24 h of surgical removal. The procedure for
isolation of epithelial cells was based on a previously described
protocol [24] with modifications. Briefly, each tissue was minced
into 1- to 2-mm pieces, digested in 1 mg/mL of collagenase-
dispase containing 1 mg/mL of DNase (Sigma) for 3 h at 37uC
with gentle stirring. Following digestion, the mixture was passed
through a 40 mm cell strainer, centrifuged (1006g for 20 min) and
resuspended in DMEM 10% FCS. After an additional centrifu-
gation step, the pellet was resuspended in keratinocyte serum-free
medium in T-25 flasks. The huPGECs were passaged twice prior
to use or frozen in aliquots to be thawed when needed.
Production of b12 minibodies and gp120 ELISA binding
assay
To produce the b12 minibodies, 293T cells were transfected
with pTR-b12scFvFc using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Sixteen hours after
transfection, the media was replaced, and the cells were further
incubated for another 48 h. The supernatant was then harvested,
sterile filtered and purified after overnight incubation at 4uC with
Protein A agarose beads (GE Healthcare, Piscataway, NJ)
according to the manufacturer’s instructions. The b12 minibodies
proteins were eluted with IgG elution buffer (Thermo Scientific,
Waltham, MA) and buffer exchanged in PBS using Amicon Ultra-
15 centrifugal filtration units (30 kDa molecular weight cut-off;
Millipore, New Bedford, MA).
The concentrations of the purified b12 minibodies and the full-
length b12 IgG1 (NIH-ARRRP) were measured using a human
IgG ELISA kit (Bethyl Laboratories, Montgomery, TX), and both
proteins were tested at equimolar concentrations for the capacity
to bind to HIV-1 bal gp120 (NIH-ARRRP) by ELISA. Ninety-six-
well microtiter plates were coated overnight at 4uC with 20 ng/
well of HIV-1 bal gp120 in 0.05 M carbonate-bicarbonate buffer
(pH 9.6, Sigma) and then blocked in PBS (1% BSA) for 1 h. Serial
dilutions of equimolar amounts of b12 IgG or b12 minibodies
were added to the plate for 1 h at room temperature. After
washing, HRP-conjugated, affinity-purified goat anti-human IgG
(Bethyl Laboratories, Montgomery, TX) was added (1:50,000) for
1 h. After extensive washing, the plate was developed by addition
of TMB substrate (Kirkegaard & Perry Laboratories, Gaithers-
burg, MD) and detected by reading the absorbance (OD) at
450 nm.
HIV-1 neutralization assay
Neutralization assays were performed by pre-incubation of
serially diluted IgG/minibodies with virus (100 TCID50) for 1 h in
100 ml of culture media (DMEM 10% FBS) prior to addition to
TZM-bl cells (approximately 50% confluent) in a final volume of
200 ml in 96-well plates. After 48 h, the cells were lysed in 50 ml
passive lysis buffer (Promega, Madison, WI) per well, and
luciferase activity was measured using the Luciferase Assay System
(Promega) on an automated luminometer (Berthold Technologies,
Bad Wildbad, Germany). The percent neutralization of a given
antibody concentration was calculated by: (Relative luciferase
activity in the absence of antibody – luciferase activity in the
presence of a given antibody concentration/luciferase activity in
the absence of antibody)6100.
Measurement of viral infectivity
TZM-bl cells, containing a luciferase gene under the control of
the HIV-1 LTR promoter, were seeded in 96-well plates
(4000 cells/well) and grown overnight. The next day, the medium
was removed, and the cells were incubated with 100 ml of either
neat or diluted media collected at different time points up to 24 h
from the lower chambers of the human vaginal organotypic VEC
transwell cultures. After 48 h of incubation, the cells were then
washed, lysed, and luciferase activity was measured as described
above for HIV-1 neutralization assays.
Results
Identification of the optimal AAV serotype for
transduction of immortalized human female genital
epithelial cell lines
To identify the most optimal AAV serotype for transduction of
female genital cells, the efficiencies of AAV 1, 2, 3, 4, 5, 6, 8 and 9
expressing GFP were evaluated by transducing immortalized
human endocervical (Endl/E6E7), ectocervical (Ectl/E6E7) and
vaginal (VK2/E6E7) epithelial cell lines. Relative transduction
efficiencies were evaluated by flow cytometry (Fig. 1A) as well as
visual assessment by fluorescence microscopy (Fig. 1D). AAV-1,
AAV-2, AAV-5 and AAV-6 were found to transduce the
endocervical, ectocervical and vaginal epithelial cell lines with
AAV-2 and AAV6 being the most efficient. By contrast, the
transduction efficiencies of AAV-3, AAV-4, AAV-8 and AAV-9
serotypes were low in these lines. In a dose dilution experiment
using AAV-6-GFP vector, transduction efficiencies of the three
genital epithelial cell lines were compared over a 100-fold range
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10 to 1610
8 genomic copies (Fig. 1B); 1610
10 genomic
copies gave the highest gene transfer efficiency and showed no
evidence of cytotoxicity (data not shown) and was chosen as the
optimal transducing units for our study. To confirm that the
inability of AAV-8 and AAV-9 to transduce the female genital cell
lines was due to their tropism for the specific cell type and not to a
defect in the vectors themselves, COS-1 cells were tested for
transduction. As shown in Fig. 1C, AAV-8-GFP and AAV-9-GFP
were able to transduce COS-1 cells effectively, indicating that both
vectors were functional.
Transduction of human primary genital-epithelial cells
(huPGEC) using AAV-6GFP
Based on the experiments above (Fig. 1A, B), AAV-6-GFP was
chosenasthemostefficient serotypetotesttransductionofhuPGEC.
Single cell suspensions of huPGEC were prepared from discarded
cervical tissues from anonymous hysterectomy patients and cultured
in serum-free keratinocyte medium as described in Materials and
Methods. Only low passage (2–3 passages) huPGEC were used for
transduction. Cells were exposed to AAV-6-GFP and found to be
efficiently transduced as determined from flow cytometric analysis of
total primary cervico-vaginal cells (Fig. 2A-B) and visual assessment
by fluorescence microscopy (data not shown).
Transduction of female human primary genital epithelial
stem cells with AAV-6-GFP
Since terminally-differentiated apical vaginal epithelial cells
continuously shed, targeting the genital epithelial stem cells for
transduction by AAV would be ideal for stable and durable gene
transfer in vivo. Accordingly, we examined whether human genital
epithelial stem cells could be transduced by AAV-6-GFP in vitro.
The isolated huPGECs were exposed to AAV-6-GFP overnight
and then stained with antibodies against the epithelial stem cell
markers, anti-CK17 and nuclear anti-p63 [25]. The stained cells
were analyzed by flow cytometry by gating first on CK17/p63
double positive cells (4.47%) (Fig. 3A) and then on the GFP-
positive cells within this population (Fig. 3B). The AAV-6-GFP
transduced cells were then sorted for further examination by
fluorescence microscopy (Fig. 3C-F). Representative images of
cells displaying the epithelial cell marker CK17 (blue), stem cell
marker p63 (red) and GFP (green) are shown in Figure 3C-E
(individual signals) and Figure 3D (merged image). These data
demonstrate that AAV-6-GFP can successfully transduce cells with
reported epithelial stem cell characteristics.
The vaginal and ectocervical stratified epithelial layers are on
average about 40 cells thick (Fig. 3G-I), and it would be
challenging for the AAV vector to reach the epithelial stem cells
in the basal layer. Therefore, AAV vector access to this stem cell
population could be enhanced by synchronous delivery timed to
the secretory phase of the menstrual cycle when thinning of the
ecto/vaginal epithelium is most evident [27]. Fortunately, the
endocervix is only one cell layer thick above the epithelial stem
cells (Fig. 3I), which is more accessible to the AAV vector during
the entire menstrual cycle.
Expression and functional evaluation of b12 minibodies
To evaluate the biological activity of b12 minibody in
comparison to that of full-length b12 IgG1, the minibodies were
produced by transient transfection of pTR-b12scFvFc into 293T
Figure 1. Transduction of human endocervical, ectocervical and vaginal epithelial cells by various AAV serotypes expressing GFP.
(A) Expressions of GFP protein by transduced cells were detected by FACS and presented as percentages of GFP positive cells. Note that AAV-2 and
AAV-6 yielded the highest transduction rates. (B) A dose dilution of AAV-6-GFP vector. (C) AAV-8-GFP and AAV-9-GFP transduction of COS-1 cells. (D)
Visual assessment of AAV-6-GFP transduction by fluorescence microscopy of vaginal, ectocervical and endocervicel cell lines.
doi:10.1371/journal.pone.0026473.g001
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expression. (A) untreated cells. (B) transduced with AAV-6-GFP.
doi:10.1371/journal.pone.0026473.g002
Figure 3. Transduction of human genital epithelial stem cells by AAV-6-GFP. At 3 days after exposure to AAV-6-GFP, cells were
stained with anti-Ck17 and anti-p63 antibodies. (A) The stained cells were analyzed by flow cytometry by gating first on CK17/p63 double
positive cells (A) and then on the GFP-positive cells within this population (B). The AAV-6-GFP transduced cells were then sorted for further
examination by fluorescence microscopy. A representative cluster of cells displaying all three distinct colors are shown: (C) blue (anti-ck17), (D) red
(anti-p63) and (E) green (GFP). (F) Merged image of C, D and E. (G-I) Immunohistochemical staining of epithelial stem cells in vaginal, ectocervical and
endocervical tissues. The p63 positively stained cells are mainly located in the basal epithelial cell layer. Note that in the endocervix (I), the epithelium
is composed of a single cell thick layer under which the epithelial stem cells are located.
doi:10.1371/journal.pone.0026473.g003
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Protein A. Both proteins were tested at equimolar concentrations
for the capacity to bind to HIV-1bal gp120. Figure 4A shows that
b12 IgG and the b12 minibody have very similar ELISA binding
curves at the concentrations used in this assay.
The capacity of b12 minibodies to neutralize HIV-1 infection in
comparison to full-length b12 IgG1 was also evaluated. Briefly,
serially diluted antibodies and 100 TCID50 HIV-1bal were mixed
in 100 ml total volumes in culture media (quadruplicate samples
for each dilution) and pre-incubated for 1 h at 37uC. The Ab-virus
mixtures were then incubated with TZM-BL cells containing a
luciferase gene under the control of the HIV-1 LTR promoter, in
96-well plates and incubated for 2 days before measuring reporter
activity of cell lysates. As shown in Figure 4B, b12 minibody
displayed identical virus neutralization activity compared with the
full-length b12 IgG1. For both antibodies, the calculated IC90
(90% Inhibitory Concentration) was 2 mg/ml, and the IC50 (50%
Inhibitory Concentration) was 0.4 mg/ml in this assay against the
HIV-1bal strain. These data confirm that the b12 minibodies can
neutralize HIV-1 similarly to the full-length b12 antibodies.
b12 minibodies interfere with HIV-1 transfer and
infectivity in the VEC tissue model
As the b12 minibody was confirmed to have the same capacity
as full-length b12 IgG1 to neutralize HIV-1 infectivity (Fig. 4B), its
activity was further compared with the full-length b12 IgG1 in
preventing HIV-1 transfer and subsequent infectivity. An
organotypic vaginal epithelial cells transwell tissue model (VEC
tissue) was used as described in Materials and Methods. After
confirming the integrity of the VEC tissues using exclusion of
70 kDa Dextran-Rhodamine from the lower chamber, b12
minibodies, full-length b12 IgG1 or irrelevant control minibodies
(each 10 mg/ml) were incubated with or without HIV-1bal virus
(50 ng) and then added to the apical surface of the organotypic
VEC tissue in transwell inserts. The media from the lower
chambers were then collected at different time points to measure
the amounts of viral particles that have crossed the VEC tissues
and to determine if they were infectious. The amounts of viral
particles were measured by p24 ELISA (Fig. 5A), and infectivity
was tested by incubation of the samples with the TZM-bl cells and
measuring luciferase gene activity as discussed previously (Fig. 5B).
In the absence of an HIV-1-specific Ab or in the presence of an
irrelevant Ab, HIV-1bal was capable of penetrating the transwell
system, as measured by p24 ELISA (Fig. 5A), and remained
infective after crossing the VEC tissues (Figure 5B). By contrast, in
the presence of either b12 minibodies or full-length b12 IgG1,
HIV-1 transfer and infectivity were inhibited (Figure 5 A-B), which
is in agreement with published data on the ability of b12 to block
early HIV-1 transfer by blocking HIV-1 viral particle binding to
syndecans expressed on the vaginal epithelial cell surface [12,15].
Interestingly, samples collected after 24 h from the control samples
had detectable amounts of p24, but failed to show infectivity in
TZM-bl cells, which is likely due to the presence of antimicrobial
peptides in epithelial cell secretions [3,7] and/or shortened half-
life of cell-free virus when they fail to rapidly encounter target cells
[9]. These findings demonstrate that b12 minibodies are
comparable to full-length b12 IgG1 in their ability to inhibit
HIV-1 transfer through vaginal epithelial cells Student’s t test was
performed and the results were found statistically significant (P-
value ,0.001).
Inhibition of HIV-1 transfer through VEC tissues and
infectivity following transduction with AAV-6 expressing
b12 minibody
In assessing the AAV-6 vectors, we first wanted to determine the
levels of b12 minibodies that could be secreted from AAV
transduced cells in the VEC model. For these studies, we obtained
commercially produced and CsCl purified AAV-6-b12minibody
and control AAV-6-11A minibody The human VEC tissues in
transwells were transduced by applying AAV-6 encoding b12
minibody or the negative control 11A minibody (5610
10 genomic
copies) to the apical surface of the tissues. Twenty-four hours later,
the tissues were washed and cultured for four days before use in
the blocking assay. Using a quantitative IgG ELISA, we confirmed
that .12 mg/ml of b12 minibody was secreted into the upper
chamber of the transwell at day 5 after transduction (data not
shown). Cell-free virus transfer and in vitro infectivity after virus
challenge were examined in the AAV transduced VEC tissue
model. HIV-1bal virus (50 ng) was applied to the apical layer, and
media from the bottom chamber was sampled at 1 h, 3 h, 6 h and
overnight. The AAV-6-b12 minibody transduced tissue effectively
blocked transfer of virus to the lower chamber, while the level of
virus transferred in the AAV-6-negative control transduced tissues
were not significantly different from that of the untreated control
(no AAV transduction) (Fig. 6A). Importantly, the supernatants in
the lower chamber of the tissues transduced with AAV-6- -b12
minibody contained little or no virus particles and were not
infectious, while those of the tissues that were untreated or
transduced with the negative control AAV had high levels of
infectious virus in the lower chambers at the 3 and 6 h time points
(Fig. 6B). This data demonstrates that recombinant AAV-6 can be
used to deliver bNAb/minibodies to primary cervical and vaginal
epithelial cells and protect against HIV-1 challenge in vitro.
Student’s t test was performed and the results were found
statistically significant (P-value ,0.001).
Figure 4. Functional comparison of b12 minibodies and full-
length b12 IgG. Both b12 minibodies and full-length b12 IgG proteins
were tested at equimolar concentrations for their capacity to (A) bind to
HIV-1 gp120 by ELISA, and (B) to neutralize HIV-1bal virus.
doi:10.1371/journal.pone.0026473.g004
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Thisstudy provides evidence that AAV-mediated gene transfer of
the human anti-gp120 b12 minibody to primary cervical and
vaginal epithelial cells can protect against virus challenge in vitro.T o
date, there is no highly effective microbicide against HIV-1
infection. Although a recent trial showed that a tenofovir containing
vaginal gel could reduce HIV-1 infection rates by 39% [28], daily
application of the gel or before and after sexual acts was impractical
for many users and adherence to the use of the gel dropped over
time. Such behavior-related issues may be avoided by delivering
anti-HIV agents with more durable activity. This present study
provides proof-of-principle for a novel microbicide strategy against
HIV-1 utilizing an AAV vector, that potentially offers long-term
stable transduction of cervico-vaginal stem cells with secretion of a
potent and broadly neutralizing anti-HIV gp120 minibody.
In preclinical animal models of human disease, AAV vectors
have emerged as a favored gene transfer system due to their safety
profile and the potential to transduce non-dividing cells. To date
there have been 12 different serotypes of AAV isolated from
human and non-human primates [29]. Different AAV serotypes
are capable of transducing a wide variety of tissue types, including
muscle, lung, brain and eye [17,18,19,20,21,22]. However,
specific AAV transduction of mucosal tissues in the female genital
tract has not yet, to our knowledge, been published. In the present
study, AAV-GFP gene transfer studies were performed on
immortalized human endocervical, ectocervical and vaginal
epithelial cell lines as well as huPGEC. Among the 8 serotypes
tested, AAV-2 and 6 were the most efficient for transduction of
these cells (Figure 1A). In this study, AAV-6 was chosen over
AAV-2 serotype because AAV-6 (a hybrid of AAV-1 and AAV-2)
has shown lower immunogenicity than AAV-2 [30], and so may
provide significant advantages over AAV-2 for gene transfer to
female genital epithelial stem cells.
The choice of utilizing the b12 mAb in this study was based on
evidence from both in vitro and in vivo studies. The in vitro studies
demonstrated that both b12 IgG1and IgA2 are able to inhibit
transfer of cell-free HIV-1 to ME-180 cells and are able to block
viral attachment to and uptake by epithelial cells [15]. Additional
evidence from macaque models indicate that the broadly
neutralizing antibody b12 IgG1 is capable of conferring protection
against SHIV infection when administered by intravenous or
Figure 5. Inhibition of HIV-1 transfer and activity by b12 minibodies in the human VEC organotypic model tissues. After a 1 h pre-
incubation of b12 minibodies or full-length b12 IgG (10 mg/ml) with HIV-1bal (50 ng), medium from the basal chambers were collected at different
time points and tested for inhibition of HIV-1bal transfer by measuring p24 content by ELISA (A) and for inhibition of virus infectivity by incubation on
TZM-bl target cells (B). Note that media collected at 3 and 6 h from tissue samples treated with HIV-1bal and b12 IgG1 antibodies or with b12
minibodies had almost completely lost their ability to infect TZM-bl cells. Irrelevant 11 A minibodies served as negative controls.
doi:10.1371/journal.pone.0026473.g005
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antibody was produced in the scFvFc (minibody) format as
opposed to full-length IgG for AAV gene transfer for several
reasons. First, as AAV vectors do not package more than ,5k bo f
foreign DNA efficiently, the AAV vector cannot accommodate
conventional antibody expression cassettes to drive the mAb heavy
chains and light chains from two individual promoters [32,33]
although, 2A sequences have been used successfully to express full-
length IgG [34,35]. Second, the minibodies are generally
expressed at high levels in mammalian cells, and third, the smaller
size of the minibodies may allow greater tissue penetration and
targeting of neutralizing epitopes that may be inaccessible or
sterically hindered as a whole IgG [36,37].
The generated b12 minibodies were confirmed to be as potent
as the full-length b12 IgG both in their capacity to bind to HIV-1
gp120 and to neutralize HIV-1bal virus (Fig. 4A, B). Furthermore,
b12 minibodies were able to block HIV-1 transfer and infectivity
of cell-free virus transferred through VEC tissues (Figs. 5 and 6).
These data are in agreement with previously published studies
[15], which showed that b12 IgG inhibited the transfer of cell free
HIV-1 through the human cervical epithelial cell line ME-180 and
that inhibition was due to the ability of IgG b12 to block both viral
attachment to and uptake by epithelial cells. In addition, studies on
rhesus macaques [16,31] demonstrated that b12 IgG applied
vaginally can afford protection against SHIV challenge. Thus, the
data clearly demonstrate that the activity of b12 minibodies is
comparable to the full-length b12 antibodies in their capacity to
inhibit in vitro transfer of cell free HIV-1 through human VEC
tissues. The findings also strongly suggest that b12 minibodies
should protect the vaginal mucosa of rhesus macaque against
SHIV challenge in planned future studies.
The present study also demonstrates that primary genital
epithelial stem cells could be transduced in vitro. This same strategy
should work effectively in vivo if the AAV vector has ready access
and sufficient time to transduce the epithelial stem cell
populations. There are two distinct epithelial stem cell populations
that differ in morphology and location. The endocervix is
naturally thin, and there is only a one cell thick layer above the
epithelial stem cells (Fig. 3I). We propose that this population of
columnar epithelial stem cells may be the most straightforward
and efficient to transduce in vivo. In contrast, the in vivo
transduction of squamous epithelial stem cells of the vaginal and
ectocervix could be less efficient due to their thick layers (Fig. 3G-
I), numerous tight junctions [38] and their continuous shedding. It
could be challenging for the AAV vectors to reach the ectocervical
and vaginal epithelial stem cells located in the basal layer. To
overcome this, AAV vectors could be applied during the secretory
phase of the menstrual cycle when mucosa is dominated by
progesterone and the cervico-vaginal layer is at its thinnest [25] or
alternatively the vector could be applied with a gene gun [39], or
on gently abraided tissue. These approaches could facilitate AAV
vector penetration and transduction of epithelial stem cells in the
basal layer. To achieve stable and durable gene transfer in vivo and
to create a milieu rich in BnAbs, transduction of the genital
epithelial stem cells in both endocervical and ectocervical/vaginal
locations may be essential for replenishing a clinically relevant
number of b12 BnAb secreting cells.
In summary, this study represents a novel HIV-1 microbicide
strategy that is both feasible and attractive in light of the absence
of a highly effective prophylactic HIV-1 vaccine. The results
provide proof of concept that AAV-BnAb gene transfer to primary
cervical and vaginal epithelial cells can protect against HIV-1
Figure 6. Inhibition of HIV-1 transfer and activity in the human VEC organotypic model tissues transduced with AAV-6 expressing
b12 minibodies. AAV-6-b12 minibodies or AAV-6-11A minibodies (control) at 5610
10 particles was applied to the upper layers of the VEC tissues for
24 h for transduction. Four days after the transduction, HIV-1bal (50 ng) was applied to the upper layers of the tissues, and medium from the basal
chambers were collected at various timepoints and tested for inhibition of viral transfer (A) and infectivity (B) as in Fig. 5.
doi:10.1371/journal.pone.0026473.g006
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transduction of cervico-vaginal epithelial stem cells highlights the
potential of this work as a means to convey durable and long-
lasting expression of BnAbs against HIV-1 in the female genital
tract. Further studies are required to examine the effectiveness of
this strategy in primate models, including testing additional BnAbs
and syndecan decoys such as those recently reported [7,14] before
moving this approach into human clinical trials. If clinically
relevant levels of anti-HIV biological agents can be achieved in
vivo, this approach may not only provide protection against HIV-1
infection but a means by which local neutralization escape, a
hallmark of HIV-1 pathogenesis, can be inhibited.
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